Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umirolimus - Biosensors International

Drug Profile

Umirolimus - Biosensors International

Alternative Names: A9; AXXESS; Ba9; BioFreedom; Biolimus A9 (BA9); Biolimus A9-drug-eluting stent; Biolimus-A-9; BioMatrix; BioMatrix Flex; BioMatrix NeoFlex; BMX-J; Custom NX; Nobori; TRM-986

Latest Information Update: 07 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosensors International Pte Ltd
  • Developer Biosensors International Group; Terumo
  • Class Macrolides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • No development reported Coronary artery disease

Most Recent Events

  • 07 Oct 2022 Biosensors Europe completes a clinical trial for Coronary artery restenosis in Switzerland and France(Intracoronary) (NCT03118895)
  • 28 Feb 2022 No recent reports of development identified for clinical-Phase-Unknown development in Coronary artery disease in Spain (Intracoronary)
  • 04 Feb 2020 Phase II development is ongoing for Coronary artery restenosis in Switzerland (NCT03118895)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top